Supriya Lifescience Limited (SUPRIYA.NS) Bundle
Supriya Lifescience's FY25 performance commands attention: revenues jumped to ₹696.48 crore (up 22% YoY) with Q3 FY25 revenue surging 33% to ₹185.65 crore, while EBITDA climbed to ₹260.80 crore with a 37.4% margin and PAT reached ₹187.96 crore (PAT margin 27%), underscoring margin expansion and operational strength; liquidity shows cash at ₹791.54 crore and current ratio improved to 5.32 even as inventories rose 38.83% to ₹118.35 crore and receivables grew 20.31% to ₹134.36 crore-factors that complicate working capital dynamics; balance sheet risk is muted with loan funds of only ₹5.38 crore and a debt‑to‑equity of 0.01, EPS climbed to ₹23.35 and shares trade at a P/E of 32.32 with market cap at ₹5,404.82 crore, while ROE sits at 18.85% against an industry average of 27.64% and growth catalysts include expansion into Europe (45% of H1 FY25 revenue), three ANDA projects in anaesthetics, and a customer base spanning 1,700+ clients across 128+ countries-dive into the full analysis to parse valuation, liquidity signals, segmental drivers and potential risks in detail.
Supriya Lifescience Limited (SUPRIYA.NS) - Revenue Analysis
Supriya Lifescience Ltd. recorded robust top-line momentum in FY25 with revenues rising to ₹696.48 crore, up 22% from ₹570.37 crore in FY24. Growth was broad-based across geographies and therapeutic segments, driven by strengthened demand in Analgesic and Anaesthetic APIs and higher traction in European markets.- FY25 total revenue: ₹696.48 crore (↑22% vs FY24 ₹570.37 crore)
- Q3 FY25 revenue: ₹185.65 crore (↑33% YoY vs Q3 FY24 ₹140.07 crore)
- Q4 FY25 revenue from operations: ₹184 crore (↑16% YoY vs Q4 FY24 ₹158 crore)
- Analgesic & Anaesthetic segment share in Q2 FY25: 54.9% (vs 50.0% in Q2 FY24)
- European contribution in H1 FY25: 45% of revenue (vs 39% in H1 FY24)
- Global footprint: operations in over 86 countries with a portfolio of 38+ active pharmaceutical ingredients
| Period | Revenue (₹ crore) | YoY Change | Notes |
|---|---|---|---|
| FY24 | 570.37 | - | Base year |
| FY25 | 696.48 | +22% | Full-year performance |
| Q3 FY24 | 140.07 | - | Quarter base |
| Q3 FY25 | 185.65 | +33% YoY | Strong quarterly growth |
| Q4 FY24 | 158.00 | - | Quarter base |
| Q4 FY25 | 184.00 | +16% YoY | Year-end quarter |
- Segment concentration: Analgesic & Anaesthetic led growth, contributing 54.9% in Q2 FY25.
- Geographic mix: Europe strengthened to 45% of H1 FY25 revenue, indicating higher export intensity and market penetration vs 39% in H1 FY24.
- Product breadth: Portfolio of 38+ APIs supports diversified revenue streams across 86+ countries.
Supriya Lifescience Limited (SUPRIYA.NS) - Profitability Metrics
Supriya Lifescience Limited delivered a notable step-up in profitability in FY25, driven by higher margins across EBITDA, operating profit and PAT, alongside improved returns to equity holders.- FY25 EBITDA: ₹260.80 crore; EBITDA margin: 37.4% (vs ₹172.98 crore and 30.3% in FY24).
- Q3 FY25 EBITDA: ₹65.95 crore, up 59% YoY; Q3 EBITDA margin expanded by 591 bps to 35.5%.
- FY25 PAT: ₹187.96 crore; PAT margin: 27.0% (vs ₹119.11 crore and 20.9% in FY24).
- Q3 FY25 PAT: ₹46.78 crore, up 57% YoY; Q3 PAT margin improved from 21.3% to 25.2%.
- Operating profit margin improved from 29.0% in FY24 to 35.42% in FY25.
- Return on Equity (ROE) as of March 2025: 18.85%, representing a 29.02% increase year-over-year.
| Metric | Q3 FY24 | Q3 FY25 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue (indicative) | - | - | - | - |
| EBITDA (₹ crore) | - | 65.95 | 172.98 | 260.80 |
| EBITDA Margin | - | 35.5% | 30.3% | 37.4% |
| PAT (₹ crore) | - | 46.78 | 119.11 | 187.96 |
| PAT Margin | 21.3% | 25.2% | 20.9% | 27.0% |
| Operating Profit Margin | - | - | 29.0% | 35.42% |
| Return on Equity (Mar‑2024 vs Mar‑2025) | - | - | 14.61% (implied) | 18.85% (up 29.02%) |
Supriya Lifescience Limited (SUPRIYA.NS) - Debt vs. Equity Structure
Supriya Lifescience Limited presents a low-leverage profile with incremental improvements across key liquidity and coverage metrics in FY25 versus FY24. The company's conservative debt posture, strong profitability and high liquidity create a capital structure that prioritizes equity funding and operational cash generation over leverage.- Loan funds decreased from ₹5.49 crore as of March 31, 2024, to ₹5.38 crore as of March 31, 2025.
- Debt-to-equity ratio stood at 0.01 as of March 31, 2025, underscoring minimal reliance on external debt.
- EBITDA/Net interest ratio improved from 81.99 in FY24 to 154.66 in FY25, indicating much stronger interest coverage.
- Current ratio increased from 5.17 in FY24 to 5.32 in FY25, reflecting improved short-term liquidity.
- Quick ratio reported as improved from 4.06 in FY24 to 3.88 in FY25.
- Net profit margin rose from 20.50% in FY24 to 26.61% in FY25, supporting equity strength and retained earnings buildup.
| Metric | FY24 | FY25 | Change |
|---|---|---|---|
| Loan Funds (₹ crore) | 5.49 | 5.38 | -0.11 |
| Debt-to-Equity Ratio | (noted) | 0.01 | - |
| EBITDA / Net Interest | 81.99 | 154.66 | +72.67 |
| Current Ratio | 5.17 | 5.32 | +0.15 |
| Quick Ratio | 4.06 | 3.88 | -0.18 |
| Net Profit Margin | 20.50% | 26.61% | +6.11 pp |
For context on the company's strategic direction that complements this capital structure, see: Mission Statement, Vision, & Core Values (2026) of Supriya Lifescience Limited.
Supriya Lifescience Limited (SUPRIYA.NS) - Liquidity and Solvency
Supriya Lifescience's balance-sheet liquidity shows moderate expansion in cash and current assets during FY25, while working-capital intensity rose due to higher inventories and receivables.- Inventories rose 38.83%: from ₹85.25 crore (31-Mar-2024) to ₹118.35 crore (31-Mar-2025), increasing the inventory turnover cycle from 165 days to 176 days.
- Trade receivables increased 20.31%: from ₹111.68 crore to ₹134.36 crore, with the debtor turnover cycle at 66 days in FY25 (vs. 64 days in FY24).
- Cash & bank balances improved 5.60%: from ₹749.56 crore to ₹791.54 crore, supporting near-term liquidity.
- Overall current assets rose 9.80%: from ₹398 crore to ₹437 crore, reflecting higher working-capital deployment.
| Item | 31-Mar-2024 | 31-Mar-2025 | Change | Notes |
|---|---|---|---|---|
| Inventories (₹ crore) | 85.25 | 118.35 | +38.83% | Inventory days: 165 → 176 |
| Trade receivables (₹ crore) | 111.68 | 134.36 | +20.31% | Debtor days: 64 → 66 |
| Cash & bank balances (₹ crore) | 749.56 | 791.54 | +5.60% | Strong cash buffer |
| Current assets (₹ crore) | 398.00 | 437.00 | +9.80% | Higher working-capital deployment |
- Implications for liquidity: improved cash balances provide coverage for short-term obligations, but rising inventories and receivables extend the cash conversion cycle.
- Solvency perspective: unless matched by higher operating cash inflows or reduced payables/borrowing, increases in working capital can pressure free cash flow and may affect leverage metrics over time.
Supriya Lifescience Limited (SUPRIYA.NS) - Valuation Analysis
Key valuation and performance metrics for Supriya Lifescience Limited (SUPRIYA.NS) provide a snapshot of how the market is pricing growth, profitability and capital returns relative to peers.
| Metric | Value / FY24 | Value / FY25 |
|---|---|---|
| Market Capitalization (as of 27-Jan-2025) | ₹5,404.82 crore | |
| Price-to-Earnings (P/E) | 32.32 | |
| Earnings Per Share (EPS) | ₹14.80 (FY24) | ₹23.35 (FY25) |
| Reported EPS (recent / trailing) | ₹21.68 | |
| Operating Profit Margin | 29.00% | 35.42% |
| Net Profit Margin | 20.50% | 26.61% |
| Return on Equity (ROE) | 18.85% (Mar 2025) | |
| Industry Average ROE | 27.64% | |
- P/E of 32.32 implies the market is assigning a premium to Supriya's earnings - investors are pricing in continued margin expansion and earnings growth.
- EPS progression from ₹14.80 (FY24) to ₹23.35 (FY25) signals strong bottom-line improvement; reported/trailing EPS of ₹21.68 provides a near-term reference.
- Operating margin rising to 35.42% and net margin to 26.61% indicates operating leverage and improved cost/realization dynamics.
- ROE at 18.85% lags the industry average of 27.64%, highlighting potential room to improve capital efficiency or signalling a different capital structure/profitability mix versus peers.
For a deeper look at shareholder composition and investor activity around Supriya Lifescience, see: Exploring Supriya Lifescience Limited Investor Profile: Who's Buying and Why?
Supriya Lifescience Limited (SUPRIYA.NS) - Risk Factors
Supriya Lifescience Limited exhibits mixed signals across operational efficiency, liquidity and profitability that investors should weigh carefully. Several metrics point to potential near-term stress in working capital management even as profitability improved markedly in FY25.- Inventory pressure: inventory turnover cycle lengthened from 165 days in FY24 to 176 days in FY25, signaling slower inventory conversion and higher carrying costs.
- Receivables build-up: trade receivables rose 20.31% - from ₹111.68 crore as of 31-Mar-2024 to ₹134.36 crore as of 31-Mar-2025 - which could strain cash flow and increase credit risk.
- Leverage and flexibility: debt-to-equity remained very low at 0.01 as of 31-Mar-2025, showing minimal financial leverage but also limited access to debt-financed growth if needed.
- Short-term liquidity: quick ratio decreased from 4.06 in FY24 to 3.88 in FY25, suggesting a slight deterioration in immediate liquidity despite very strong levels overall.
- Overall current liquidity: current ratio improved from 5.17 in FY24 to 5.32 in FY25, indicating ample short-term coverage of current liabilities but possibly signaling excess idle working capital.
- Profitability upside: net profit margin expanded from 20.50% in FY24 to 26.61% in FY25, reflecting better pricing, cost control or a favorable product mix - a mitigating factor versus working capital concerns.
| Metric | FY24 | FY25 | Change / Note |
|---|---|---|---|
| Inventory turnover cycle (days) | 165 | 176 | +11 days - slower turns |
| Trade receivables (₹ crore) | 111.68 | 134.36 | +20.31% - higher receivables |
| Debt-to-equity ratio | - | 0.01 | Minimal leverage (0.01 as of 31-Mar-2025) |
| Quick ratio | 4.06 | 3.88 | Decline in immediate liquidity |
| Current ratio | 5.17 | 5.32 | Improved short-term coverage |
| Net profit margin | 20.50% | 26.61% | Significant margin expansion |
Supriya Lifescience Limited (SUPRIYA.NS) - Growth Opportunities
Supriya Lifescience Limited has been actively positioning itself for sustained, diversified growth across regulated and non-regulated markets by leveraging product development, manufacturing scale-up, geographic expansion and targeted capital allocation.- Global commercial footprint: servicing over 1,700 customers across more than 128 countries, providing geographic diversification and multiple revenue channels.
- Pipeline development: initiated three ANDA projects in the Anaesthetic therapy segment; additional ANDA projects in Anti‑Hypertensive and Vitamins under development.
- Capacity & site expansion: acquisition of three separate land parcels adjacent to existing plants to support future capacity, backward integration and new product lines.
- Operational improvements: focus on commercializing newly scaled-up products, enhancing operational efficiency via automation, and leveraging R&D capabilities to shorten time-to-market.
- Strategic priorities: sustain momentum while strengthening global footprint, with emphasis on ESG, robust quality systems and deeper customer engagement.
| Initiative | Key Facts / Metrics | Current Status | Expected Impact |
|---|---|---|---|
| Global Customer Base | >1,700 customers; >128 countries | Active commercial relationships across regulated & non-regulated markets | Revenue diversification; reduced single‑market risk |
| ANDA Pipeline - Anaesthetic | 3 ANDA projects initiated | Development / regulatory filing stages | Access to higher‑margin regulated market opportunities |
| ANDA Pipeline - Other Therapies | Projects for Anti‑Hypertensive and Vitamins | Preclinical / formulation and scale‑up | Broader therapeutic coverage and product lifecycle extension |
| Land Acquisitions | 3 land parcels acquired near plants | Land secured; development to follow CAPEX scheduling | Capacity expansion, specialized facilities, localisation of operations |
| Operational Automation & Scale‑up | Investment in automation and R&D scale‑up | Ongoing; commercialization of scaled products underway | Lower unit costs, improved throughput, faster time‑to‑market |
| ESG & Quality Systems | Enhanced quality controls and ESG focus | Continuous improvement initiatives | Improved customer confidence and access to regulated buyers |
- Commercialization roadmap: priority given to newly scaled-up products to convert R&D and CAPEX investments into recurring revenue streams.
- Customer engagement: leveraging a 1,700+ customer base to upsell new formulations and capture larger wallet share per account.
- R&D leverage: pursuing ANDA filings to transition from contract manufacturing toward higher-value generic markets.
Supriya Lifescience Limited (SUPRIYA.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.